The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | How mutation screening impacts transplant decisions in MDS
Pramila Krishnamurthy, MD, King’s College Hospital NHS Foundation Trust, London, UK, talks on mutation screening in myelodysplastic syndromes (MDS) and its impact on transplantation. Dr Krishnamurthy first comments on the impact of monoallelic and biallelic p53 mutation in MDS, and the need to better understand the impact of post-transplant therapies in these patients. Following this, Dr Krishnamurthy discusses the debate around deciding which patients with adverse-risk profiles should go to transplant, and how post-transplant strategies, such as maintenance therapy with azacitidine, can modify poor outcomes. To conclude, Dr Krishnamurthy discusses the emergence of the molecular international prognostic scoring system (IPSS-M), which will be increasingly used for MDS risk stratification. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Ad board- Jazz
Honorarium- Astellas, Jazz
